Radiopharm Theranostics Ltd (RAD) - Total Liabilities
Based on the latest financial reports, Radiopharm Theranostics Ltd (RAD) has total liabilities worth AU$41.23 Million AUD (≈ $29.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Radiopharm Theranostics Ltd (RAD) net asset momentum to track the company's year-over-year net asset growth rate.
Radiopharm Theranostics Ltd - Total Liabilities Trend (2021–2025)
This chart illustrates how Radiopharm Theranostics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Radiopharm Theranostics Ltd Competitors by Total Liabilities
The table below lists competitors of Radiopharm Theranostics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Mercantile Investment Trust plc
LSE:MRC
|
UK | GBX336.42 Million |
|
Cherrybro co.Ltd
KQ:066360
|
Korea | ₩188.30 Billion |
|
Daishin Information & Communications Co.Ltd
KQ:020180
|
Korea | ₩116.84 Billion |
|
Victor Group Holdings Ltd
AU:VIG
|
Australia | AU$6.95 Million |
|
Biotoxtech Co. Ltd
KQ:086040
|
Korea | ₩98.39 Billion |
|
Scope Industries Bhd
KLSE:0028
|
Malaysia | RM13.57 Million |
|
Beamr Imaging Ltd. Ordinary Share
NASDAQ:BMR
|
USA | $965.00K |
|
PIL ITALICA LIFESTYLE LIMITED
NSE:PILITA
|
India | Rs264.43 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Radiopharm Theranostics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Radiopharm Theranostics Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Radiopharm Theranostics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Radiopharm Theranostics Ltd (2021–2025)
The table below shows the annual total liabilities of Radiopharm Theranostics Ltd from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$43.61 Million ≈ $30.86 Million |
-2.40% |
| 2024-06-30 | AU$44.68 Million ≈ $31.62 Million |
+52.14% |
| 2023-06-30 | AU$29.37 Million ≈ $20.78 Million |
+43.84% |
| 2022-06-30 | AU$20.42 Million ≈ $14.45 Million |
+12811.62% |
| 2021-06-30 | AU$158.14K ≈ $111.89K |
-- |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more